HER2 and HER3 Conformational Domain Bridging Epitopes in Antibodies via an Exclusive Option Allows Hillstream BioPharma to Develop Proprietary Multi-format Biologics (bispecific, ADC, CAR-T) against Drug Resistant Breast and Gastric Cancers
Anti-HER2 and Anti-HER3 monoclonal antibodies could be effective against a number of epithelial tumors including HER2-positive metastatic breast cancer, gastric cancer, lung cancer and ovarian cancer
Antibody CDRs against HER2 and HER3 Conformational Domain Bridging Epitopes can be used in multiple formats including bi- and tri-specific antibodies, ADCs (antibody drug conjugates), CAR-T and CAR-NKs, as well as in Quatramers™ and Quatrabodies™
https://finance.yahoo.com/news/hillstream-biopharma-signs-exclusive-option-121100940.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.